|Reference : No-Carrier-Added Regioselective Preparation of 6-[18f]Fluoro-L-Dopa|
|Scientific journals : Article|
|Human health sciences : General & internal medicine|
|No-Carrier-Added Regioselective Preparation of 6-[18f]Fluoro-L-Dopa|
|Bozet, Claire [Centre Hospitalier Universitaire de Liège - CHU > > O.R.L. >]|
|Guillaume, Marcel [> > > >]|
|Cantineau, R. [> > > >]|
|Christiaens, Léon [Université de Liège - ULg > Services généraux (Faculté des sciences) > Relations académiques et scientifiques (Sciences) >]|
|Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|
|[en] This paper describes the preparation of 6-[18F]fluoro-L-dopa by a no-carrier-added method based on the nucleophilic displacement of nitro groups of two commercially available substrates, 3,4-dimethoxy-2-nitrobenzaldehyde (nitroveratraldehyde) and 6-nitropiperonal. Fluorination was conducted in DMSO with fluorine-18 (18F) in the presence of the aminopolyether Kryptofix 222 and potassium carbonate. The condensation of the fluorinated aldehydes with phenyloxazolone and the subsequent hydrolysis with HI/P yield, after purification by HPLC, only the 6-(D, L) isomers. The racemic mixture (50/50) was resolved on an analytical scale chiral column. The method, which requires 100 min (EOB) to complete, produces 6-[18F]fluoro-L-dopa with a decay-corrected radiochemical yield of 10%, an enantiomeric purity greater than 99%, and a specific activity of 1.2 Ci/mumole.|
There is no file associated with this reference.
All documents in ORBi are protected by a user license.